nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
1 |
A Case of Familial Hypoalphalipoproteinemia with Significant Premature Atherosclerosis
|
Rahman, Tahmid |
|
|
18 |
4S |
p. e505-e506 |
artikel |
2 |
Accelerated Atherosclerosis in a Patient With Multifactorial Chylomicronemia Syndrome (MCS), Elevated Lp(a), APOE2/4 Genotype and Diabetes Mellitus.
|
Roth, Mendel |
|
|
18 |
4S |
p. e538 |
artikel |
3 |
*Achievement of Low-Density Lipoprotein Cholesterol (LDL-C) Thresholds in Patients with Very High-Risk Atherosclerotic Cardiovascular Disease (ASCVD)
|
Saseen, Joseph |
|
|
18 |
4S |
p. e550-e551 |
artikel |
4 |
A Controlled Intervention Restricting AGEs Improves Carboxymethyl Lysine, RAGE, Lipid, and Inflammatory Indices in Patients Undergoing Hemodialysis
|
Aroni, Adamantia |
|
|
18 |
4S |
p. e548 |
artikel |
5 |
A Father's Last Message: The Value of Polygenic Risk Scoring in Familial CAD
|
Soffer, Daniel |
|
|
18 |
4S |
p. e503-e504 |
artikel |
6 |
†Age- and Sex-Specific Nomographic CT Quantitative Plaque Data From a Large International Cohort
|
Tzimas, George |
|
|
18 |
4S |
p. e578-e579 |
artikel |
7 |
A Novel Nanoparticle Lipoprotein Free Cholesterol Mass Transfer Assay
|
Neufeld, Edward |
|
|
18 |
4S |
p. e580-e581 |
artikel |
8 |
A Patient who is Nonresponsive to PSCK9 Inhibition by both mAb and RNAi
|
Gianos, Eugenia |
|
|
18 |
4S |
p. e507 |
artikel |
9 |
†A Pilot Study of Triglyceride Screening in Blood Donors
|
Eason, Stephen |
|
|
18 |
4S |
p. e532 |
artikel |
10 |
Apo E Genotyping and Cardiovascular Risk Re-Classification of Subjects, A Single Center Experience 2008-2022
|
Shaish, Aviv |
|
|
18 |
4S |
p. e485-e486 |
artikel |
11 |
A Rare Encounter: Familial Lipoprotein Lipase Deficiency in Pregnancy - Case Review and Emerging Therapies for Familial Chylomicronemia Syndrome
|
Rajpal, Aman |
|
|
18 |
4S |
p. e502 |
artikel |
12 |
ASCVD Risk Reduction in Patients with Immune-Mediated Inflammatory Disease: A Retrospective Quality Assessment Study
|
Monzer, Nasser |
|
|
18 |
4S |
p. e510-e511 |
artikel |
13 |
ASCVD Risk Stratification in a Large Urban Clinic – Role of CACS in Reclassifying Black versus White Individuals Seen for Preventive Care.
|
Peters, Matthew |
|
|
18 |
4S |
p. e512-e513 |
artikel |
14 |
†Assessment of Unmet Clinical Needs and Healthcare Resource Use among Statin-Treated Patients with or at Risk of Developing ASCVD
|
Rambo, Bob |
|
|
18 |
4S |
p. e519-e520 |
artikel |
15 |
Association Between Niacin-ER Use, Safety, and Cardiovascular Events. A Single Center Experience.
|
Caraang, Chris |
|
|
18 |
4S |
p. e554-e555 |
artikel |
16 |
Atlantic Lipid Lowering Treatment Optimization Program (ALLTOP): A Comprehensive Approach to the Treatment of Familial Hypercholesterolemia and Comple
|
Proute, Matthew |
|
|
18 |
4S |
p. e493-e494 |
artikel |
17 |
Atrial Fibrillation Outcome in Patients with Metabolic Syndrome.
|
Somoza-Cano, Francisco |
|
|
18 |
4S |
p. e556 |
artikel |
18 |
Attitudes and Barriers to Lipoprotein(a) Testing: A Survey of Providers at the University of Pennsylvania Health System
|
Bajaj, Archna |
|
|
18 |
4S |
p. e487-e488 |
artikel |
19 |
*Calculated Small Dense LDL-C has a Stronger Association to Atherosclerotic Cardiovascular Events than other Components of the Lipid Panel.
|
Sampson, Maureen |
|
|
18 |
4S |
p. e499-e500 |
artikel |
20 |
Cardiovascular Outcomes Unveiled: Bempedoic Acid in Hyperlipidemia—A Comprehensive Updated Systematic Review and Meta-analysis of RCTs
|
Ali, Saba |
|
|
18 |
4S |
p. e570-e571 |
artikel |
21 |
†Cardiovascular Trials Over the Last 15 years: Analysis of the Characteristics and Trends of ClinicalTrials.gov Listings from 2008 to 2022
|
Allaham, Laith |
|
|
18 |
4S |
p. e549-e550 |
artikel |
22 |
Centralized Cascade Screening for Familial Hypercholesterolemia: Perspectives of Patients and Providers
|
Brown, Ashley |
|
|
18 |
4S |
p. e544-e545 |
artikel |
23 |
Clinical Outcomes And Mortality in Heart Failure And Chronic Kidney Disease Patients Admitted With Non-Variceal Upper Gastrointestinal Bleeding
|
Hijazi, Mohamad |
|
|
18 |
4S |
p. e520 |
artikel |
24 |
Clinical Outcomes in Patients Admitted with Acute Coronary Syndrome Affected by Protein Calorie Malnutrition.
|
Rahima, Kenan |
|
|
18 |
4S |
p. e528 |
artikel |
25 |
Clinical Outcomes in Patients admitted with Diabetes Mellitus and Chronic Kidney Disease Affected by Non-Alcoholic Fatty Liver Disease
|
Hijazi, Mohamad |
|
|
18 |
4S |
p. e529-e530 |
artikel |
26 |
Comparative Assessment of hsCRP and Apolipoprotein B as ASCVD Risk Biomarkers
|
Amusat, Saheed |
|
|
18 |
4S |
p. e499 |
artikel |
27 |
Comparison of Package Insert versus Real World Safety Data from Branded Icosapent Ethyl Users: A Select Analysis Utilizing MarketScan Data
|
Nelson, John |
|
|
18 |
4S |
p. e574 |
artikel |
28 |
Coronary Artery Disease in Familial Hypoalphalipoproteinemia: A Case Report
|
Moussa, Sumer |
|
|
18 |
4S |
p. e504 |
artikel |
29 |
Detailed Family History of Premature Atherosclerotic Cardiovascular Disease to Guide Lipoprotein(a) Testing: The Multi-Ethnic Study of Atherosclerosis
|
Bhatia, Harpreet |
|
|
18 |
4S |
p. e486-e487 |
artikel |
30 |
Development of a Clinical Diagnostic Score for Familial Chylomicronemia Syndrome (FCS)
|
Campos, Cynthia |
|
|
18 |
4S |
p. e536 |
artikel |
31 |
Development of the Family Heart Foundation™ Flag, Identify, Network, Deliver—Familial Hypercholesterolemia (FIND-FH™) Implementation Toolkit
|
MacDougall, Diane |
|
|
18 |
4S |
p. e495-e496 |
artikel |
32 |
Differences in Clinical Outcomes between Non-Obese African American and Asian Populations Who have Hyperlipidemia
|
Khokhlov, Leonid |
|
|
18 |
4S |
p. e558-e559 |
artikel |
33 |
Differences in Clinical Outcomes between Non-Obese Caucasian and Asian Populations Who have Hyperlipidemia
|
Khokhlov, Leonid |
|
|
18 |
4S |
p. e558 |
artikel |
34 |
+Differences in Clinical Outcomes between Non-Obese Caucasian and Hispanic Populations Who have Hyperlipidemia
|
Khokhlov, Leonid |
|
|
18 |
4S |
p. e557 |
artikel |
35 |
Differences in Clinical Outcomes Between Non-Obese Caucasians and African American Populations with Hyperlipidemia
|
Khokhlov, Leonid |
|
|
18 |
4S |
p. e576-e577 |
artikel |
36 |
Differences in Clinical outcomes between Non-Obese Hispanic and Asian populations Who have Hyperlipidemia
|
Khokhlov, Leonid |
|
|
18 |
4S |
p. e559-e560 |
artikel |
37 |
Discrepancies in Prescribing Practices for SGLT2 Inhibitors Between Sexes
|
Rege, Rahul |
|
|
18 |
4S |
p. e515 |
artikel |
38 |
Effect of Diabetes Mellitus (T2DM) Medications on Lipid Parameters in Veterans with T2DM and Metabolic Dysfunction Associated Steatotic Liver Disease (MASLD)
|
Ubalde, Shannen Nicole |
|
|
18 |
4S |
p. e493 |
artikel |
39 |
Elevated Levels of Lp(a) are Associated with Circulating Levels of PCSK9 and Coronary Atherosclerosis as Detected by Cardiac Computed Tomography Angiography
|
Brown, Bradley |
|
|
18 |
4S |
p. e577-e578 |
artikel |
40 |
Elevated Serum Small Dense Low Density Lipoprotein Cholesterol and Lipoprotein(a) Levels in Preeclampsia
|
Wolfe, Elizabeth |
|
|
18 |
4S |
p. e498-e499 |
artikel |
41 |
†Evaluation of Chenodeoxycholic Acid Treatment in Adult Patients with Cerebrotendinous Xanthomatosis: A Randomized, Placebo-Controlled Phase 3 Study
|
DeBarber, Andrea |
|
|
18 |
4S |
p. e540-e541 |
artikel |
42 |
Exploring the Impact of Gender and BMI on Apolipoprotein B in Adult Subjects
|
Amusat, Saheed |
|
|
18 |
4S |
p. e518-e519 |
artikel |
43 |
FADS2 Indel Polymorphism rs66698963 Predicts Colorectal Polyp Prevention by the n-3 Fatty Acid EPA
|
Block, Robert |
|
|
18 |
4S |
p. e535-e536 |
artikel |
44 |
Familial Hypercholesterolemia: Can Continuing Medical Education Help Address Barriers to Screening in Children?
|
Morris, Pamela |
|
|
18 |
4S |
p. e537-e538 |
artikel |
45 |
Familial Hypercholesterolemia Cascade: On the Road to Universal Screening
|
Proute, Matthew |
|
|
18 |
4S |
p. e542-e543 |
artikel |
46 |
Familial Hypercholesterolemia Diagnosis and Management: Insights from the NIH Precision Medicine Initiative All of Us Study
|
Block, Robert |
|
|
18 |
4S |
p. e539 |
artikel |
47 |
Fellow Quality Improvement Project: Identification of High Risk CAD Patients and Referral to Newly Established Lipid Clinic, What are the Clinical Implications?
|
Rinehart, Sarah |
|
|
18 |
4S |
p. e581-e582 |
artikel |
48 |
Fenofibric Acid has Distinct Molecular Location in Reconstituted Liver Membranes and Higher Affinity Compared to Pemafibrate
|
Sherratt, Samuel |
|
|
18 |
4S |
p. e573-e574 |
artikel |
49 |
†Food Compass Score is Inversely Related to Inflammatory Markers and Cardiovascular Disease Incidence: Results from the ATTICA Cohort Study (2002-2022)
|
Damigou, Evangelia |
|
|
18 |
4S |
p. e529 |
artikel |
50 |
Genetic Testing Results in a Preventative Cardiology and Inherited Lipid Disorders Clinic
|
Elysee, Isaac |
|
|
18 |
4S |
p. e540 |
artikel |
51 |
Health Outcomes and Survival of Patients with Severe Hypertriglyceridemia after Acute Pancreatitis
|
Chang, Eunice |
|
|
18 |
4S |
p. e486 |
artikel |
52 |
†High Rates of Cardiovascular Events in Patients with Multivessel Disease in the First Year Post-Myocardial Infarction: A Systematic Literature Review
|
Korjian, Serge |
|
|
18 |
4S |
p. e518 |
artikel |
53 |
Impact of Familial Hypercholesterolemia on Coronary Artery Dissection in Patients Undergoing Percutaneous Coronary Intervention (PCI)
|
Yang, Chris |
|
|
18 |
4S |
p. e534-e535 |
artikel |
54 |
+Impact of Grant-Funded Coronary Artery Calcium Score on Cardiovascular Risk Assessment and Management in an Underserved Population
|
Ambrosino, Maxwell |
|
|
18 |
4S |
p. e511-e512 |
artikel |
55 |
Impact of Non-Alcoholic Fatty Liver Disease on Heart Failure Hospitalizations: Insights from the National Inpatient Sample Database
|
Yang, Chris |
|
|
18 |
4S |
p. e534 |
artikel |
56 |
^Improving Risk Stratification in Severe Hypercholesterolemia: Provider Recommendations for Developing a Program to Communicate ASCVD Risk
|
Salvati, Zachary |
|
|
18 |
4S |
p. e508-e509 |
artikel |
57 |
†Interaction of AI-Enabled Quantitative Coronary Plaque Analysis Volumes on Coronary CT Angiography, FFRCT, and Clinical Outcomes: A Retrospective Analysis of the ADVANCE Registry
|
Huey, Whitney |
|
|
18 |
4S |
p. e579-e580 |
artikel |
58 |
Lipid lowering Injectable Clinic-Novel Idea for Improving Compliance with Twice Yearly Dosing of Inclisiran
|
Ali, Ahmad |
|
|
18 |
4S |
p. e495 |
artikel |
59 |
Lipoprotein (a) Discovery Project: Initiative to Identify Awareness and Models of Lipoprotein (a) Testing for National Education
|
Pena, David |
|
|
18 |
4S |
p. e489-e490 |
artikel |
60 |
Lipoprotein(a)’s Prediction of Cardiovascular Disease Events When Accessed via Electronic Health Records
|
Block, Robert C |
|
|
18 |
4S |
p. e555 |
artikel |
61 |
Lomitapide in Pediatric Patients with Homozygous Familial Hypercholesterolemia – Analysis of Secondary and Safety Endpoints from the APH-19 Study
|
Schmitt, Claus |
|
|
18 |
4S |
p. e545-e546 |
artikel |
62 |
Lower Activity of Cholesteryl Ester Transfer protein (CETP) and the Risk of Dementia: A Mendelian Randomization Analysis
|
Hsieh, Andrew K |
|
|
18 |
4S |
p. e577 |
artikel |
63 |
Multidisciplinary Management of Lipoprotein X-Induced Hyperlipidemia Secondary to Drug-Induced Liver Injury
|
Kim, Samuel |
|
|
18 |
4S |
p. e502-e503 |
artikel |
64 |
Negative LDL-C levels with Detectable Apolipoprotein B: Surrogate Markers of Atherosclerotic Disease and Cardiac Event Risk
|
Haynes, Tiffany |
|
|
18 |
4S |
p. e501-e502 |
artikel |
65 |
†Not Published
|
|
|
|
18 |
4S |
p. e550 |
artikel |
66 |
Obicetrapib Alone and with Ezetimibe Reduces Non-HDL-C by Enhanced LDL-Receptor-Mediated VLDL Clearance and Increased Net Fecal Sterol Excretion
|
Keijzer, Nanda |
|
|
18 |
4S |
p. e552 |
artikel |
67 |
†Obicetrapib Demonstrates Significant Reductions Of Lp(a) On Top Of High-intensity Statins
|
Hsieh, Andrew |
|
|
18 |
4S |
p. e563-e564 |
artikel |
68 |
†Obicetrapib Does Not Accumulate in Adipose Tissue: Results from Studies in Man and Non-human Primates
|
Hsieh, Andrew |
|
|
18 |
4S |
p. e563 |
artikel |
69 |
†Obicetrapib Treatment Increases Pre-Beta1 HDL and Lipophilic Antioxidants in the Ocean and Rose2 Studies
|
Ditmarsch, Marc |
|
|
18 |
4S |
p. e566-e567 |
artikel |
70 |
Oleocanthal-Rich Olive Oil's Effect on Postprandial Platelet Activity and Oxidative Stress Markers of Type 2 Diabetic Patients
|
Detopoulou, Paraskevi |
|
|
18 |
4S |
p. e576 |
artikel |
71 |
Optimizing Residual Cardiovascular Risk in a Case of Homozygous Familial Hypercholesterolemia (HoFH) and Elevated Lipoprotein (a) [Lp(a)]
|
Hasham, Salman |
|
|
18 |
4S |
p. e539-e540 |
artikel |
72 |
Pancreatitis Polygenic Risk Score is Associated with Acute Pancreatitis in Multifactorial Chylomicronemia Syndrome
|
Paquette, Martine |
|
|
18 |
4S |
p. e537 |
artikel |
73 |
Patient Experience with Familial Chylomicronemia Syndrome before and after Olezarsen Treatment: Qualitative Interviews with Clinical Trial Participants
|
Brown, T. Michelle |
|
|
18 |
4S |
p. e568-e569 |
artikel |
74 |
Patients Admitted with Acute pancreatitis and Dyslipidemia Affected by Non-Alcoholic Fatty Liver Disease are Associated with Worse Clinical Outcomes
|
Hijazi, Mohamad |
|
|
18 |
4S |
p. e532-e533 |
artikel |
75 |
†Patients Perceive a Considerable Treatment Burden in the First Year after a Myocardial Infarction: Results from an Online US Patient Survey
|
Korjian, Serge |
|
|
18 |
4S |
p. e550 |
artikel |
76 |
*Pericardial and Pleural Effusions after Evolocumab in a Patient with Severe Familial Hypercholesterolemia
|
Pavlovic, Maia |
|
|
18 |
4S |
p. e506-e507 |
artikel |
77 |
†Pharmacological Trials for the Treatment or Prevention of Coronary Artery Disease: Analysis of ClinicalTrials.gov Listings from 2008 to 2022
|
Bahit, M. Cecilia |
|
|
18 |
4S |
p. e548-e549 |
artikel |
78 |
†Plozasiran (ARO-APOC3), an Investigational RNAi, Demonstrates Deep and Durable TG Reductions in Patients With SHTG, SHASTA-2 Final Results
|
Pall, Denes |
|
|
18 |
4S |
p. e564 |
artikel |
79 |
†Plozasiran (ARO-APOC3), an Investigational RNAi, Demonstrates Robust and Durable TG Reductions in Patients with Mixed Dyslipidemia, MUIR Final Results
|
Vasas, Szilard |
|
|
18 |
4S |
p. e560 |
artikel |
80 |
Population Analysis of Patients at a Multidisciplinary Prevention Center: Insights, Gaps, and Opportunities
|
Burkle, Jaime |
|
|
18 |
4S |
p. e490-e491 |
artikel |
81 |
Potential of High Sensitivity C-Reactive Protein in Early Assessment of ASCVD Risk among Prediabetic Patients
|
Amusat, Saheed |
|
|
18 |
4S |
p. e497 |
artikel |
82 |
Process Mapping the Lipid Management Patient Pathway in Six Health Systems for Identification of Barriers to Guideline-Directed Care
|
Overton, Katherine |
|
|
18 |
4S |
p. e488 |
artikel |
83 |
Protein Calorie Malnutrition Effect on Clinical Outcomes And Resource Utilization in Patients Admitted with Acute Pancreatitis And Dyslipidemia
|
Hijazi, Mohamad |
|
|
18 |
4S |
p. e533-e534 |
artikel |
84 |
+Racial Inequities in Coronary Artery Calcium Screening and Follow-up
|
Umer, Muhammad |
|
|
18 |
4S |
p. e513-e514 |
artikel |
85 |
Racial Variations in SGLT2 Inhibitor Prescriptions
|
Leung, Christian |
|
|
18 |
4S |
p. e514-e515 |
artikel |
86 |
Rates of Lipid Testing among Patients with Atherosclerotic Cardiovascular Disease within a Large Community-Based Health System
|
Li, Hsin-Fang |
|
|
18 |
4S |
p. e492 |
artikel |
87 |
†Real-World Effectiveness and Safety of Evinacumab in Patients with Homozygous Familial Hypercholesterolemia: A Multi-site US Perspective
|
Bijlani, Priyesha |
|
|
18 |
4S |
p. e567-e568 |
artikel |
88 |
Real-World Evaluation of Lipid Testing Rate and Treatment Target Attainment Among High-Risk Patients: Post Release of the 2018 AHA/ACC Practice Guidelines
|
Visaria, Jay |
|
|
18 |
4S |
p. e494-e495 |
artikel |
89 |
Real-world Experience of Inclisiran at the University of Pennsylvania Health Systems
|
Risman, Marjorie |
|
|
18 |
4S |
p. e491-e492 |
artikel |
90 |
*Real-World Experience with Inclisiran at a Large Academic Lipid Clinic
|
Wilkinson, Michael |
|
|
18 |
4S |
p. e553-e554 |
artikel |
91 |
Real World Experience with Inclisiran in an Academic Medical Center
|
Bartsch, Kelly |
|
|
18 |
4S |
p. e551-e552 |
artikel |
92 |
Rethinking Prevention: Need for earlier intervention in Familial Hypercholesteremia despite Statin and PCSK9 Inhibitor Therapy
|
Proute, Matthew |
|
|
18 |
4S |
p. e543 |
artikel |
93 |
Role and Expression of 15-Prostaglandin Dehydrogenase in Cartilage tissue
|
Alsabri, Sami |
|
|
18 |
4S |
p. e572-e573 |
artikel |
94 |
†Role of DNA methylation on 15-Lipoxygenase-1 gene expression in Osteoarthritis
|
Alsabri, Sami |
|
|
18 |
4S |
p. e571-e572 |
artikel |
95 |
†Role of Epigenetic Regulation and Sp1 Rranscription Factor on DP1 Receptor Expression in Osteoarthritis
|
Alsabri, Sami |
|
|
18 |
4S |
p. e572 |
artikel |
96 |
Severe Medication Induced Dyslipidemia in an Adult with Breast Cancer
|
Sheth, Sohum |
|
|
18 |
4S |
p. e555-e556 |
artikel |
97 |
Study Design of a Phase 3 Randomized Controlled Trial Evaluating the Efficacy and Safety of Pegozafermin in Patients with Severe Hypertriglyceridemia
|
Hartsfield, Cynthia |
|
|
18 |
4S |
p. e552-e553 |
artikel |
98 |
†Synergistic Effect of Obicetrapib and Ezetimibe on Circulating LDL Particles
|
Hsieh, Andrew |
|
|
18 |
4S |
p. e566 |
artikel |
99 |
Tailored Therapeutic Strategies for the Management of Chylomicronemia Syndrome
|
Skariah, Annie |
|
|
18 |
4S |
p. e504-e505 |
artikel |
100 |
The Advancing Cardiac Care Unit-based Rapid Assessment and Treatment of hypErcholesterolemia (ACCURATE) Study – Phase 1 Results
|
Iatan, Iulia |
|
|
18 |
4S |
p. e546-e547 |
artikel |
101 |
The Exception that Proves the Rule: Acute Myocardial Infarction in a Person at Extremely Low Risk for Plague Rupture
|
Proute, Matthew |
|
|
18 |
4S |
p. e501 |
artikel |
102 |
The Family Heart Foundation™ Flag, Identify, Network, Deliver—Familial Hypercholesterolemia (FIND-FH™) Program and Collaborative Learning Network (CL
|
MacDougall, Diane |
|
|
18 |
4S |
p. e496-e497 |
artikel |
103 |
The Food Compass Score is Negatively Related to the Activity of Lipoprotein-Associated Phospholipase A2 (Lp-PLA2) in Healthy Adults.
|
Fragopoulou, Elizabeth |
|
|
18 |
4S |
p. e573 |
artikel |
104 |
The IMPACT of Virtual Reality and Other Immersive Tools to Improve the Multidisciplinary Team's Ability to Screen, Diagnose, and Manage FH
|
Allen, Russie |
|
|
18 |
4S |
p. e489 |
artikel |
105 |
The Lomitapide Observational Worldwide Evaluation Registry (LOWER) - Nine-year Effectiveness and Safety Data in HoFH
|
Underberg, James |
|
|
18 |
4S |
p. e545 |
artikel |
106 |
The Long-Term Efficacy and Safety of Evinacumab in Pediatric Patients with Homozygous Familial Hypercholesterolemia
|
Greber-Platzer, Susanne |
|
|
18 |
4S |
p. e554 |
artikel |
107 |
The Outcome of Coronary Artery Bypass Graft in Patient with Prediabetes.
|
Smith, Brittany |
|
|
18 |
4S |
p. e557-e558 |
artikel |
108 |
†The Role of Structured Inpatient Lipid Protocols in Optimizing Non-Statin Lipid Lowering Therapy: A Review and Single-Center Experience
|
Gier, Chad |
|
|
18 |
4S |
p. e516-e518 |
artikel |
109 |
The Value of Lipid Testing in Recognizing Residual Risk
|
Zias, Ariadne |
|
|
18 |
4S |
p. e510 |
artikel |
110 |
Treatment Patterns Among Early Inclisiran vs Anti–PCSK9 mAbs Users: A Retrospective Analysis of US Claims Databases
|
Popadic, Lyuba |
|
|
18 |
4S |
p. e515-e516 |
artikel |
111 |
Trends in Age-Adjusted Cardiovascular Mortality Rates with Hyperlipidemia among the United States Population, from 1999–2023: A CDC Wonder Database Study
|
Brands, Chad |
|
|
18 |
4S |
p. e530-e532 |
artikel |
112 |
Trends of Global Disease Burden Attributable to Diet low in Polyunsaturated fatty Acidsl From 1990 to 2019: A Global Burden of Disease Study Analysis
|
Abu-Haniyeh, Ahmed |
|
|
18 |
4S |
p. e520-e521 |
artikel |
113 |
Unexpected High Cardiovascular Risk in a Healthy Young Patient
|
Jacoby, Douglas |
|
|
18 |
4S |
p. e507-e508 |
artikel |
114 |
Unique Case of Familial Hypobetalipoproteinemia (FHBL)
|
Soffer, Daniel |
|
|
18 |
4S |
p. e543-e544 |
artikel |
115 |
Unmasking the Silent Culprit: Lipoprotein(a) Elevation in a Previously Healthy Individual
|
Arrigo, Alexis |
|
|
18 |
4S |
p. e506 |
artikel |
116 |
†Utility of AI-QCPA: Results of the Decisions for Treating Coronary Disease are Changed in Patients Evaluated with Quantified Plaque Analysis
|
Blankstein, Ron |
|
|
18 |
4S |
p. e581 |
artikel |
117 |
Utilizing hsCRP as a Diagnostic Tool for Managing ASCVD: Exploring its Relationships with Cardiometabolic Risk Factors
|
Amusat, Saheed O |
|
|
18 |
4S |
p. e498 |
artikel |
118 |
Xanthelasma Associated with Defective Reverse Cholesterol Transport, Resolution with Rosuvastatin/Ezetimibe: A Case Report
|
Doyle, Michael |
|
|
18 |
4S |
p. e541-e542 |
artikel |